文献速递儿科影像神经PETCT

18F-氟脱氧葡萄糖正电子发射断层显像/计算机断层显像对伴神经母细胞瘤的儿童眼阵挛肌阵挛共济失调综合征的诊断价值

Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging in pediatric opsoclonus myoclonus ataxia syndrome presenting with neuroblastoma.
PubMed 文献 · Pediatr Radiol · 2024-04-13

该研究回顾性评估了45例眼阵挛肌阵挛共济失调综合征(OMAS)患儿的18F-FDG PET/CT,其中27例PET/CT阳性,23例经证实为神经母细胞瘤,4例为假阳性。PET/CT诊断神经母细胞瘤的敏感度100%、特异度81.8%、准确率91.1%;乳酸脱氢酶为独立危险因素,临床模型AUC 0.82,联合PET/CT后AUC达0.91。

要点

  • OMAS患儿行18F-FDG PET/CT,阳性病灶平均最大标准化摄取值为2.6。
  • PET/CT诊断神经母细胞瘤敏感度100%、特异度81.8%、准确率91.1%。
  • 血清乳酸脱氢酶为独立危险因素,联合PET/CT的列线图AUC达0.91。

核心结论

  • 在OMAS患者中,18F-FDG PET/CT检测神经母细胞瘤具有较高的诊断准确性,尤其当联合独立危险因素血清乳酸脱氢酶时。

研究设计与样本

  • 回顾性评估45例诊断为OMAS并接受18F-FDG PET/CT的患者;采用单因素分析比较伴与不伴神经母细胞瘤的OMAS临床特征,单因素和多因素logistic回归识别独立危险因素并构建临床模型,再将独立危险因素与PET/CT拟合构建联合模型并绘制列线图;用受试者工作特征曲线、决策曲线和校准曲线评价模型性能。

关键影像表现/征象

  • 45例中27例PET/CT阳性,其中23/27例病灶为神经母细胞瘤,4例为假阳性。
  • 假阳性患者中1例经术后病理证实为肾上腺反应性增生,其余3例在临床随访期间OMAS症状消失。
  • PET/CT阳性病灶的平均最大标准化摄取值为2.6。

诊断标准与关键数值

  • PET/CT诊断神经母细胞瘤的敏感度100%、特异度81.8%、阳性预测值85.2%、阴性预测值100%、准确率91.1%。
  • 伴与不伴神经母细胞瘤的OMAS在诊断时年龄、乳酸脱氢酶和神经元特异性烯醇化酶方面差异有统计学意义。
  • 乳酸脱氢酶被确定为独立危险因素并用于构建临床模型,该模型诊断OMAS伴神经母细胞瘤的AUC为0.82,联合PET/CT后AUC高达0.91。

临床应用与阅片要点

  • 在OMAS患者中,18F-FDG PET/CT对检测神经母细胞瘤具有较高的诊断准确性,尤其当联合独立危险因素血清乳酸脱氢酶时。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Early precision diagnosis and effective treatment of opsoclonus myoclonus ataxia syndrome (OMAS) patients presenting with neuroblastoma can prevent serious neurological outcomes.

OBJECTIVE: To assess the diagnostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging in pediatric OMAS with neuroblastoma.

MATERIALS AND METHODS: A retrospective evaluation of 45 patients diagnosed with OMAS who underwent 18F-FDG PET/CT was performed. A univariate analysis was performed to compare clinical characteristics between OMAS with and without neuroblastoma. Univariate and multivariate logistic regression analyses were applied to identify independent risk factors for OMAS with neuroblastoma and to develop the clinical model. Finally, independent risk factors and PET/CT were fitted to build the combined model for the diagnosis of OMAS with neuroblastoma and presented as a nomogram. Receiver operating characteristic curve, decision curve, and calibration curve analyses were conducted to evaluate the performance of the models.

RESULTS: Among 45 patients, 27 were PET/CT-positive, 23/27 lesions were neuroblastoma, and four were false positives. One of the false positive patients was confirmed to be adrenal reactive hyperplasia by postoperative pathology, and the symptoms of OMAS disappeared in the remaining three cases during clinical follow-up. The average maximal standardized uptake value of PET/CT-positive lesions was 2.6. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of PET/CT were 100%, 81.8%, 85.2%, 100%, and 91.1%, respectively. Age at diagnosis, lactate dehydrogenase, and neuron-specific enolase showed statistically significant differences between OMAS with and without neuroblastoma. Lactate dehydrogenase was identified as the independent risk factor to develop the clinical model, and the clinical model demonstrated an area under the curve (AUC) of 0.82 for the diagnosis of OMAS with neuroblastoma, with an AUC as high as 0.91 when combined with PET/CT. The decision curve analysis and calibration curve demonstrated that the nomogram had good consistency and clinical usefulness.

CONCLUSION: In patients with OMAS, 18F-FDG PET/CT has a high diagnostic accuracy in detecting tumors of the neuroblastoma, especially when combined with the independent risk factor serum lactate dehydrogenase.

来源:Pediatr Radiol,查看原文。版权归原作者所有。

引用

  1. Feng L, Yang S, Lin Y, et al. Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging in pediatric opsoclonus myoclonus ataxia syndrome presenting with neuroblastoma. Pediatr Radiol. 2024. PMID: 38613691. doi:10.1007/s00247-024-05921-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。